Surface plasmon resonance for the label-free detection of Alzheimer’s β-amyloid peptide aggregation

Amyloid peptide oligomers and fibrils are studied as targets for therapy and diagnosis of Alzheimer’s disease. They are usually detected by amyloid incubation, but such method is necessarily associated with Aβ1–42 depletion and dye binding or conjugation, which have a complex influence on fibril growth, provide information about fibril elongation over long time periods only, and might lead to false-positive results in amyloid inhibition assay. Surface plasmon resonance (SPR) is used to study with no labelling and in real time the aggregation of Aβ1–42 amyloid on specific antibodies. SPR data show, for the first time by using SPR, a multi-phase association behavior for Aβ1–42 oligomers accounting for a sigmoidal growth of amyloid as a function of time, with two antibody-dependent aggregation patterns. The new method represents an advantageous alternative to traditional procedures for investigating amyloid self-assembly and inhibition from early-stage oligomer association, on the time scale of seconds to minutes, to long-term polymerization, on the time scale of hours to days.

[1]  M. Gobbi,et al.  Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ(1-42) peptide, synthesized by depsi-peptide technique. , 2011, Biosensors & bioelectronics.

[2]  Min-Gon Kim,et al.  Surface plasmon resonance analysis of Alzheimer's beta-amyloid aggregation on a solid surface: from monomers to fully-grown fibrils. , 2008, Analytical chemistry.

[3]  Y. Ihara,et al.  γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment , 2009, The Journal of Neuroscience.

[4]  Alexander K. Buell,et al.  Biosensor‐based label‐free assays of amyloid growth , 2009, FEBS letters.

[5]  Giuseppe Spoto,et al.  Surface plasmon resonance imaging for nucleic acid detection , 2012, Analytical and Bioanalytical Chemistry.

[6]  T. Wengenack,et al.  Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid β peptide capturing- and plaque binding-monoclonal antibodies , 2009, Alzheimer's & Dementia.

[7]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[8]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[9]  K. Blennow,et al.  Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease , 2013, PloS one.

[10]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[11]  Zhiyuan Hu,et al.  Label-free detection of Alzheimer's disease through the ADP3 peptoid recognizing the serum amyloid-beta42 peptide. , 2015, Chemical communications.

[12]  H. Kung,et al.  Congo red and thioflavin‐T analogs detect Aβ oligomers , 2007 .

[13]  M. Groenning,et al.  Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils—current status , 2010, Journal of chemical biology.

[14]  Roland Winter,et al.  Solvation-assisted pressure tuning of insulin fibrillation: from novel aggregation pathways to biotechnological applications. , 2006, Journal of molecular biology.

[15]  Kenjiro Ono,et al.  Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. , 2002, Biochemistry.

[16]  C. Ionescu-Zanetti,et al.  Surface-catalyzed Amyloid Fibril Formation* , 2002, The Journal of Biological Chemistry.

[17]  Ronald Wetzel,et al.  Kinetic analysis of beta-amyloid fibril elongation. , 2004, Analytical biochemistry.

[18]  M. Fändrich,et al.  The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation , 2005, Protein science : a publication of the Protein Society.

[19]  A. Bonvin,et al.  The α‐to‐β Conformational Transition of Alzheimer's Aβ‐(1–42) Peptide in Aqueous Media is Reversible: A Step by Step Conformational Analysis Suggests the Location of β Conformation Seeding , 2006 .

[20]  A. Bush,et al.  Enzyme solid-state support assays: a surface plasmon resonance and mass spectrometry coupled study of immobilized insulin degrading enzyme , 2009, European Biophysics Journal.

[21]  K. Matsuzaki,et al.  “Click Peptide“: pH‐Triggered in Situ Production and Aggregation of Monomer Aβ1–42 , 2009, Chembiochem : a European journal of chemical biology.

[22]  Richard W. Clarke,et al.  Direct characterization of amyloidogenic oligomers by single-molecule fluorescence , 2008, Proceedings of the National Academy of Sciences.

[23]  M. Perugini,et al.  Phospholipid interaction induces molecular-level polymorphism in apolipoprotein C-II amyloid fibrils via alternative assembly pathways. , 2008, Journal of molecular biology.

[24]  Shinichiro Nakamura,et al.  Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses* , 2011, The Journal of Biological Chemistry.

[25]  B. Graves,et al.  Equilibrium analysis of high affinity interactions using BIACORE. , 1998, Analytical biochemistry.

[26]  Ville Leinonen,et al.  Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. , 2010, Journal of Alzheimer's disease : JAD.

[27]  I. Lindberg,et al.  The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related Proteins , 2012, The Journal of Biological Chemistry.

[28]  M. Mattson,et al.  Deglycosylated anti‐amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration , 2007, The European journal of neuroscience.

[29]  Ruth Nussinov,et al.  Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s , 2015, Nature Structural &Molecular Biology.

[30]  John M Finke,et al.  Kinetic analysis of IgG antibodies to beta-amyloid oligomers with surface plasmon resonance. , 2015, Analytical biochemistry.

[31]  D. Selkoe,et al.  Preventing Alzheimer’s Disease , 2012, Science.

[32]  K. Lam,et al.  Congo red and thioflavin-T analogs detect Abeta oligomers. , 2008, Journal of Neurochemistry.

[33]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[34]  M. Leone,et al.  Thioflavin T Promotes Aβ(1-40) Amyloid Fibrils Formation. , 2012, The journal of physical chemistry letters.

[35]  P. Aisen,et al.  Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. , 2004, Biochemical and biophysical research communications.

[36]  R. Finke,et al.  Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. , 2009, Biochimica et biophysica acta.

[37]  Nicholas W. Smith,et al.  Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly. , 2012, ACS chemical neuroscience.

[38]  A. Sheikh,et al.  Lysophosphatidylcholine modulates fibril formation of amyloid beta peptide , 2011, The FEBS journal.

[39]  Judianne Davis,et al.  Structural conversion of neurotoxic amyloid-β(1–42) oligomers to fibrils , 2010, Nature Structural &Molecular Biology.